Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SIM0505 in Advanced Solid Tumors
NCT06792552Phase 1Recruiting
- Sponsor
- NextCure, Inc.
- Start
- Feb 2025
- Primary completion
- Feb 2028
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 2
01
Overview
Phase 1, open-label trial of SIM0505 in solid tumor, ovarian cancer, fallopian tube cancer (PFTC) and 5 more (5 arms), sponsored by NextCure, Inc. Primary endpoints: Dose-limiting toxicity at 3 weeks, Adverse events at 2 years and 1 more. Started Feb 2025; status: recruiting.
02
Drugs
SIM0505
03
Conditions
solid tumorovarian cancerfallopian tube cancer (PFTC)renal cell carcinoma (RCC)papillary renal cell carcinoma (PRCC)
Beyond the preview
Go deeper on NCT06792552.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06792552.